The mechanism suggested that CREBBP/EP300 mutation inhibited H3K27 acetylation, downregulated FBW7 expression, and activated the Notch pathway, ultimately promoting DLBCL proliferation. Here, FBXW7 is linked to diffuse large B-cell lymphoma.